UI CEO’s rapturous to work with Blue Digital Media"We are happy to have access to Blue Digital's distribution channels, as their range across borders will broaden awareness of our business to new audiences," said Nick Karos, UI's Chief Executive Officer. Because addiction knows no bounds, the remedy we seek must be global in scope." As Blue Digital Media professional radar.
Daytrading
$IBO CO-Founder with wide ranging work-experienceDr. Sola, a co-founder of Universal Ibogaine and a member of its Board of Directors, has effectively administered over 3,700 ibogaine treatments, more than any other doctor in the world, at an independent clinic in Cancun, Mexico, where he is a partner.
$IBO’S CEO comments on the H.C Wainwright"H.C. Wainwright is a leader in the field and may be a significant strategic partner in our ongoing corporate finance roadmap," said Nick Karos, CEO of Universal Ibogaine. Another crucial step in raising awareness of our brand and service is the chance to share our story with this audience.
CEO highlights on the sheer extent of the research to reality ev"The significance of this occasion cannot be emphasized," said CEO Nick Karos. This is the first gathering of academic researchers, real-world technicians, and government policymakers of its sort. This event will raise awareness of ibogaine's great potential at the highest levels."
$HEM announcement related to the Stock Options GrantHemostemix Inc. announced that in accordance with its stock option plan, it has granted on February 28, 2022, subject to regulatory approval, a total of 1,494,269 stock options to purchase common shares of Hemostemix to directors, officers, employees and consultants of Hemostemix
$IBO, Recognized as a powerful addiction interrupterOur mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.
While seeking to move Ibogaine through Clinical Trials in Canada, we are building a network of holistic recovery clinics and a state of the art treatment program centred around new treatment modalities.
Potential aptitude of NCP-01 by Hemostemix Neuropathic pain synNeuropathic pain syndromes can be treated with NCP-01 and its autologous stem cell technology, which can treat disorders of the central and peripheral nervous systems. Spinal cord injury, chronic brainstem injury, traumatic brain injury, and peripheral nerve injury are all examples of traumatic injuries and many more
$IBO and its revolutionary addiction treatment protocolUI is developing an advanced holistic addiction treatment protocol, at its Kelburn Recovery Centre, that when combined with the planned ibogaine detox methodology is expected to transform the way we treat addiction and dramatically promote the welfare of families affected by addiction.
$IBO soon to commission ultra- modern addiction treatment centreAt the Kelburn Clinic, UI is developing a cutting-edge holistic addiction treatment protocol that, when combined with the anticipated ibogaine detox programme, will transform the way we treat addiction and dramatically enhance the lives of individuals and families plagued by addiction.
Hemostemix Inc. interest payment on convertible debentureHemostemix Inc. announced that it will pay interest of $84,804.40 by issuing 446,339 Common Shares, using the March 2, 2022 closing price of $0.19 per share, to the convertible debenture holder in satisfaction of interest due on the outstanding principal amount of $2,500,000 for the period from inception, June 11, 2021, to December 31, 2021.